This treatment significantly reduces Treg frequency, diminishes the production of TGF-β and IL-10 by Tregs, and also safeguards tumor-antigen-specific CD8+ T cells from tumor-induced deletion in the context of HCC [131,132]. The gene discussed is IL10; the disease is neoplasm.